Generic Drugmakers
- All
- News
- Videos
-
Australia's Mayne Pharma Sues India's Sun Pharma Over Patent Infringement
Mayne Pharma has filed a lawsuit against India's Sun Pharma over infringements of patents related to a certain product used for menopause-related vaginal pain, the Australian drugmaker said on Thursday.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Gilead Ties Up With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Incsaid on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
-
Billionaire Father, Son Turn 10-Storey Mumbai Office Into World Beater
Cadila's stock delivered returns of almost 50 percent, making it the best among generic drugmakers worldwide with a market value of more than $1 billion.
-
Lupin Looks To Clean Up Its Act As FDA Steps Up Inspections
Often dubbed "the pharmacy of the world", India is home to the most FDA-approved plants outside of the United States
-
Andhra Pradesh High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The Andhra Pradesh High Court on Saturday lifted a temporary stay it imposed on generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of Ranbaxy Laboratories Ltd, a lawyer involved in the case said, paving the way for both companies to complete the deal.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Patent board rules against Bayer in cancer drug case
A patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.
-
Australia's Mayne Pharma Sues India's Sun Pharma Over Patent Infringement
Mayne Pharma has filed a lawsuit against India's Sun Pharma over infringements of patents related to a certain product used for menopause-related vaginal pain, the Australian drugmaker said on Thursday.
-
Merck's Anti- Covid Pill 'Molflu' 5-Day Course To Cost Rs 1,400 In India
Drugmaker Dr Reddy's Laboratories Ltd will launch its generic version of Merck's antiviral COVID-19 pill, molnupiravir.
-
1st Covid Vaccine For Children Above 12 Approved In India
India's drug regulator on Friday approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country.
-
3 Indian Firms To Make, Sell US's Eli Lilly's Baricitinib Drug For Covid Treatment
Eli Lilly and Co said on Monday it had signed licensing agreements with three Indian generic drugmakers to expand the availability of its arthritis drug baricitinib in the country for treating COVID-19 patients.
-
Merck Taps 5 Indian Drugmakers To Expand Covid Drug Production
Merck & Co Inc said on Tuesday it had partnered with five Indian generic drugmakers, including Cipla Ltd and Sun Pharmaceutical Industries Ltd, to expand production and access to its experimental COVID-19 drug.
-
India's Shortage Of Remdesivir Is Easing, Says Producer Cipla
India's supply of antiviral drug remdesivir and generic equivalents is stabilising after shortages of the vital COVID-19 medicine at hospitals, according to a top executive at one of the country's big drugmakers, Cipla Ltd.
-
Cipla Set To Undercut Rivals With Generic Remdesivir: Sources
Indian drugmaker Cipla Ltd has priced its generic version of Remdesivir, Cipremi, at 4,000 rupees ($53.34) per 100 mg vial, according to several sources, making it among the lowest priced versions of the COVID-19 treatment available so far globally.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Maharashtra, Delhi Among 5 States To Receive First Batch Of COVID-19 Drug
Hyderabad-based drugmaker Hetero, which has approval to manufacture and market the generic version of the experimental COVID-19 drug Remdesivir, has sent 20,000 vials to five states including Maharashtra and Delhi - the two worst affected states in the country.
-
Gilead Ties Up With Drugmakers In India, Pak For Making Remdesivir
Gilead Sciences Incsaid on Tuesday it has signed non-exclusive licensing pacts with five generic drugmakers based in India and Pakistan to expand the supply of its experimental COVID-19 treatment remdesivir.
-
Billionaire Father, Son Turn 10-Storey Mumbai Office Into World Beater
Cadila's stock delivered returns of almost 50 percent, making it the best among generic drugmakers worldwide with a market value of more than $1 billion.
-
Lupin Looks To Clean Up Its Act As FDA Steps Up Inspections
Often dubbed "the pharmacy of the world", India is home to the most FDA-approved plants outside of the United States
-
Andhra Pradesh High Court Lifts Stay on Sun Pharma's $3.2 Billion Ranbaxy Takeover
The Andhra Pradesh High Court on Saturday lifted a temporary stay it imposed on generic drugmaker Sun Pharmaceutical Industries Ltd's $3.2 billion takeover of Ranbaxy Laboratories Ltd, a lawyer involved in the case said, paving the way for both companies to complete the deal.
-
Ranbaxy to pay $500 million in US lawsuit settlement
Generic drugmaker Ranbaxy Laboratories Ltd pleaded guilty on Monday to felony charges related to drug safety and will pay $500 million in civil and criminal fines under the settlement agreement with the US Department of Justice.
-
Patent board rules against Bayer in cancer drug case
A patent appeals board upheld on Monday a decision to allow a domestic company to sell a generic version of Bayer AG's cancer drug Nexavar, in a blow for global drugmakers' efforts to hold on to monopolies on high-price medicines.
